Position in ENGN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$11,833
-$73,067 QoQ
Shares Held
6,840
-45.1% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#55
of 60 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ENGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026WELLS FARGO & COMPANY/MN holds $1,567,775,044 across 417 Biotechnology names. ENGN ranks #316 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
749,528 | $372,313,040 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
1,390,428 | $108,828,797 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
310,047 | $93,333,446 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
140,802 | $87,795,677 | |
| 5 | EXEL |
Exelixis, Inc.
|
717,840 | $39,057,673 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
178,780 | $33,481,916 | |
| 7 | ARGX |
Argenx SE
|
34,453 | $31,964,458 | |
| 8 | INCY |
Incyte Corp
|
255,064 | $28,914,053 |
All Filings in ENGN
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $11,833 | 6,840 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $84,900 | 12,467 | Shares | Defined | 2026-05-11 | |
| 2025-12-31 | $101,289 | 11,217 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $122,325 | 17,910 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $11,644 | 3,199 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $8,606 | 1,921 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $7,567 | 1,138 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $7,510 | 1,138 | Shares | Defined | 2024-11-13 | |
| 2024-06-30 | $9,165 | 972 | Shares | Defined | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||